Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 3 records in total 3
    records per page




    Acute Pancreatitis HP Pancreatitis MESHD may Occur in COVID-19 Patients with Clearance of SARS-CoV-2 in Lung: A Case Report

    Authors: Hong Zhao; Junwei Su; Kaijin Xu; Yu Shi; Yunqing Qiu; Jifang Sheng

    doi:10.21203/rs.3.rs-62816/v1 Date: 2020-08-20 Source: ResearchSquare

    Background: Severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), is mostly causes lung damages, but also lead to gastroenterology injury MESHD. SARS-CoV-2 - associated acute pancreatitis HP pancreatitis MESHD has been reported, however, clearance of SARS-CoV-2 and the pancreatitis HP pancreatitis MESHD was not clear.Case presentation: A 62 year old diabetic MESHD female TRANS patient suffer from coronavirus diseases MESHD (COVID-19) and detection of SARS-CoV-2 turned negative on day 11 and day 12 in sputum. Two days latter, the patient was diagnosed with acute pancreatitis HP acute pancreatitis MESHD. Through the support treatment, the patient got better and discharged from our hospital 18 days later.Conclusions: Our case provided an initial view of SARS-CoV-2 infection MESHD with acute pancreatitis HP pancreatitis MESHD and the acute pancreatitis HP pancreatitis MESHD may occur in COVID-19 patients with clearance of SARS-CoV-2 in lung.

    Patients with COVID-19 Interstitial Pneumonia HP Exhibit Pancreatic Hyperenzymemia MESHD and Not Acute Pancreatitis HP Pancreatitis MESHD

    Authors: Raffaele Pezzilli; Stefano Centanni; Michele Mondoni; Rocco F. Rinaldo; Matteo Davì; Rossana Stefanelli; GianVico Melzi d’Eril; Alessandra Barassi

    doi:10.21203/rs.3.rs-50275/v1 Date: 2020-07-28 Source: ResearchSquare

    Background and aims: Gastrointestinal manifestations of COVID-19 have been well established, but pancreatic involvement MESHD is under debate. The aim of the study is to evaluate the presence of acute pancreatitis HP pancreatitis MESHD in COVID-19 patients and to assess the frequency of pancreatic hyperenzymemia MESHD. Methods: From April 1st 2020 to April 30th 2020, 110 consecutive patients (69 males TRANS, 41 females TRANS; mean age TRANS 63.0 years, range 24-93 years) met these criteria and were enrolled in the study.. The clinical data and serum SERO activity of pancreatic amylase and lipase were assayed in all patients using commercially available kits. Results: None of the patients studied developed clinical signs or morphological alterations compatible with acute pancreatitis HP pancreatitis MESHD. However, it was found that 24.5% of the patients had amylase values above 53 IU/L and 16.4% had lipase values above 300 IU/. Only one patient (0.9%) had both amylase and lipase values in excess of three-fold the upper normal limit without clinical signs of pancreatitis HP pancreatitis MESHD. Conclusions: The presence of pancreatic hyperenzymemia MESHD in a patient with COVID-19 requires the management of these patients be guided by clinical evaluation and not merely by evaluation of the biochemical results.

    COVID-19, What Could Sepsis HP Sepsis MESHD, Severe Acute Pancreatitis HP Pancreatitis MESHD, Gender TRANS Differences and Aging Teach Us?

    Authors: Claudio Gallo; Sirio Fiorino; Giovanni Posabella; Donato Antonacci; Antonio Tropeano; Emanuele Pausini; Carlotta Pausini; Tommaso Guarniero; Marco Zancanaro

    id:202007.0414/v1 Date: 2020-07-19 Source: Preprints.org

    Severe COVID-19 disease is characterised by an exaggerated inflammatory response, called cytokine storm, accompanied by a condition of immune depression MESHD. Even sepsis HP sepsis MESHD is characterised by an exaggerated inflammatory response, called SIRS (Systemic Inflammatory Response Syndrome), accompanied by a condition of immune depression MESHD called CARS (compensatory anti-inflammatory response syndrome). Clinical studies reveal that most sepsis HP sepsis MESHD patients who did not die during the hyper inflammatory response ( SIRS MESHD) subsequently succumbed to the condition of immune depression MESHD (CARS). Severe acute pancreatitis HP pancreatitis MESHD begins with local inflammation MESHD that induces systemic inflammatory response syndrome ( SIRS MESHD), accompanied and followed by a compensatory anti-inflammatory response (CARS). In COVID-19 disease, the male TRANS response to SARS CoV-2 virus is typically characterised by a robust inflammatory response. Instead, a cell-mediated immune response is dominant in women. This means that the male TRANS sex tends to have a more robust hyper inflammatory response than the female TRANS one. Furthermore, in women the condition of immune depression MESHD is less represented, therefore they are more protected. Sepsis HP Sepsis MESHD, severe acute pancreatitis HP pancreatitis MESHD and COVID-19 disease evolve between two fundamental aspects: hyper inflammation and immunodepression MESHD. The experience gained over years of studies of sepsis HP sepsis MESHD and severe acute pancreatitis HP pancreatitis MESHD suggests that therapies should be differentiated according to the evolutionary stage of the disease. The goal is to save the lives of most patients with COVID-19 disease. The identification of critical points, suitable for designing the windows of therapeutic opportunity, may allow the use of therapeutic interventions, in the COVID-19 disease, which are effective (there are no approved drugs yet), safe (without significant side effects), targeted (based on the evolutionary phase of the disease) personalized, (based on sex, co-morbidities, age TRANS, etc.) and timely (based on signs, symptoms, laboratory parameters and instrumental investigations).

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.